The company transitioned from outsourcing manufacturing to operating its own manufacturing facility to improve control over the supply chain, flexibility, timelines, and intellectual property protection. Since 2014, it has engaged in partner-initiated programs to develop its platform and build a diversified portfolio of royalties and stakes in antibody medicines developed by partners. Partnership agreements typically include payments for access, research, intellectual property rights, clinical and commercial milestones, and royalties on net sales. Beginning in 2023, the company reduced discovery partnerships to focus on its internal pipeline while continuing to fulfill obligations from multi-year agreements and remaining open to high-value collaborations. As of December 31, 2025, the company initiated 104 partner-initiated programs with downstream participation and produced 19 molecules that have reached clinical trials using its capabilities and technology, including the Trianni humanized rodent platform. Investments in technology, development of multiple drugs, and long-term value creation are central to the company’s strategy.
Abcellera Biologics Inc's Comment on Supply Chain
The company transitioned from outsourcing manufacturing to operating its own manufacturing facility to improve control over the supply chain, flexibility, timelines, and intellectual property protection. Since 2014, it has engaged in partner-initiated programs to develop its platform and build a diversified portfolio of royalties and stakes in antibody medicines developed by partners. Partnership agreements typically include payments for access, research, intellectual property rights, clinical and commercial milestones, and royalties on net sales. Beginning in 2023, the company reduced discovery partnerships to focus on its internal pipeline while continuing to fulfill obligations from multi-year agreements and remaining open to high-value collaborations. As of December 31, 2025, the company initiated 104 partner-initiated programs with downstream participation and produced 19 molecules that have reached clinical trials using its capabilities and technology, including the Trianni humanized rodent platform. Investments in technology, development of multiple drugs, and long-term value creation are central to the company’s strategy.
Sources:
Abcellera Biologics Inc 's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Abcellera Biologics Inc ’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
